Saraton antigeni (CA) 15-3
Kod:10002|CPT:86300|LOINC:6875-9
| Kabi | Saraton antigeni 15-3 (CA 15-3) |
|---|
Tahlil ma'lumotlari
Tadqiqot usuli
- Elektrokimyoluminessent immunoanaliz (ECLIA)
- Kimyoluminessent immunoanaliz (CLIA)
Kutilayotgan natija topshirish vaqti
1 kun
Maxsus tayyorlik
- Use the same assay method for all serial measurements; do not compare results across different methods.
- This order code is for a single measurement; for ongoing serial monitoring, order 483404.
- Review biotin use; stop high-dose biotin for at least 72 hours before specimen collection.
- Fast for 8 hours; water is allowed.
- Avoid physical exertion and minimize emotional stress for 30 minutes before collection.
- Do not smoke for 24 hours prior to collection.
Qanday foydalanish
Saraton antigeni 15-3 (CA 15-3) testi ushbu o'sma markerining miqdoriy qiymatini beradi. Har bir namuna olishda bir xil analiz usuli qo'llanilganda, ketma-ket o'lchovlar bemorning davolash kursi va umumiy kasallik holatini monitoring qilishga xizmat qiladi. Turli analiz platformalaridan olingan natijalar o'zaro almashtirilmasligi kerak. CA 15-3 qiymatlari o'z-o'zicha yovuz o'smani na tasdiqlaydi, na inkor etadi va ularni klinik baholash hamda boshqa diagnostik tadqiqotlar bilan birga talqin qilish zarur. Keng qo'llaniladigan sinonimlarga CA 15-3 va "cancer antigen 15-3" tumor markeri kiradi.
Cheklovlar
CA 15-3 konsentrasiyalari, sonli qiymatidan qat'i nazar, yovuz o'sma kasalligini qat'iy tasdiqlamaydi yoki inkor etmaydi. Talqin qilish uchun bemorning anamnezi, ko'rik natijalari va boshqa diagnostik protseduralar bilan integratsiya talab etiladi. Trend tahlili barcha ketma-ket o'lchovlar bir xil analiz bilan bajarilganda eng ma'noli bo'ladi, chunki turli usullar turlicha sonli natijalar berishi mumkin. Yuqori dozalardagi biotin biotin-streptavidin immunoanalizlarida asossiz past qiymatlarga olib kelishi mumkin; biotin bilan bog'liq xalaqit xavfini kamaytirish uchun namuna ushbu qo'shimchalarni to'xtatgandan kamida 72 soat o'tgach olinishi lozim.
| Referens oraliq |
| ||||
|---|---|---|---|---|---|
| Ko'rsatmalar | Baseline measurement and serial follow-up of CA 15-3 to track response to therapy and disease course using the same assay method., Single, quantitative determination of CA 15-3 when a one-time assessment is requested., Adjunctive use with clinical evaluation and other diagnostic procedures; not intended to diagnose malignancy. |
Natija og'ishlarining mumkin sabablari
Pasaygan daraja
- biotin
Namunangiz talablari
| Namunangiz | Zardob |
|---|---|
| Container | Oltin/yo'lbars qopqoqli probirka (SST, gel ajratgich) |
| Hajm | 1 mL (min 0.7 mL) |
| Saqlash tayyorlik | Xona harorati, Sovutilgan, Muzlatilgan |
References
Hayes DF, Zurawski VR Jr, Kufe DW. Comparison of circulating CA 15-3 and carcinoembryonic antigen levels in patients with breast cancer. J Clin Oncol. 1986;4(10):1542-50. PubMed 2428949.
Strausberg RL. Cancer Genomics: Disease Markers. IOS Press, 2002.
Shi, Shan-Rong; Taylor, Clive R. Antigen Retrieval Immunohistochemistry Based Research and Diagnostics. Wiley Dewey, 2010.
Hayat MA. Methods of Cancer Diagnosis, Therapy, and Prognosis. Springer Dewey, 2010.
Ouyang DL, Chen JJ, Getzenberg RH, Schoen RE. Noninvasive testing for colorectal cancer: a review. Am J Gastroenterol. 2005;100:1393-403.
Atkin W. Options for screening for colorectal cancer. Scand J Gastroenterol. 2003;237:13-6.
Lamberti C, Sauerbruch T. Early diagnosis of colorectal tumours. Internist (Berlin). 2005;46:401-10.
Clark SK, Carpenter S, Broughton CI, Marks CG. Surveillance of individuals at intermediate risk of colorectal cancer: the impact of new guidelines. Colorectal Dis. 2003;5:582-4.